OneVentures, an Australian venture capital firm, has appointed IP and commercial specialist Sakura Holloway and former Shire Pharmaceuticals Scout Sarah Meibusch to the healthcare investment management team.
The appointments provide additional capacity to source, structure and manage healthcare sector opportunities for the recently launched $170M OneVentures Healthcare Fund III, which is focused on investing in Australian companies commercialising drugs, medical devices and diagnostics in or near clinical development stage.
Sakura Holloway has joined OneVentures following two years as Chief IP Counsel at dual-listed Australian biotech company Benitec Biopharma Ltd, where her achievements included managing the company’s IP portfolio and supporting the US IPO and NASDAQ listing.
A registered patent attorney, Holloway’s previous positions have included scientific roles with UTS and the Garvan Institute, and IP/commercial roles with Cephalon, CSIRO and FB Rice.
She joins OneVentures as an Investment Analyst providing specialist expertise in IP due diligence and management to the team alongside considerable commercial skills and experience.
Sarah Meibusch joins the OneVentures team in the role of Investment Manager. Meibusch’s previous responsibilities included five years scouting for technologies for Shire Pharmaceuticals within Australia, New Zealand, Singapore, Taiwan, Korea and Japan including sourcing the $300M Fibrotech deal.
With an understanding of the pharmaceutical, life sciences, medtech and healthcare industries gained through senior roles at Progen Pharmaceuticals, University of Queensland, the Beef CRC and Pyxis Genomics she will be based in OneVenture’s Queensland office but will operate nationally.
Led by Anne-Marie Birkill, Managing Partner, Dr Michelle Deaker and Dr Paul Kelly, OneVentures is an Australian venture capital firm with $320M under management, launching its first fund in 2010. It has three main funds, two of which are actively investing. The OneVentures Innovation and Growth Fund II and OneVentures Healthcare Fund III, have approximately $200M in available capital for technology and healthcare businesses. The OneVentures Healthcare Fund III, launched in December 2016, is a $170M fund licenced under the Commonwealth Government’s Biomedical Translation Fund (BTF) program and is actively seeking investments in Australian companies commercializing medical devices, drugs in clinical development and diagnostics.